Features September 2015 Issue

New Cholesterol-lowering Drugs Help Those Intolerant to Statins

PCSK9 inhibitors may also bring about changes to cholesterol treatment guidelines that have moved away from specific LDL targets for patients.

Two new cholesterol-lowering drugs may do more than provide alternatives for people who have serious side effects from statins. PCSK9 inhibitors may also help bring back specific targets in cholesterol treatment guidelines. When the American College of Cardiology and the American Heart Association developed new cholesterol guidelines with the National Heart, Lung, and Blood Institute in 2013, the changes included the eliminiation of specific targets for LDL (“bad”) cholesterol and HDL (“good”) cholesterol.

To continue reading this article you must be a paid subscriber.

Subscribe to Heart Advisor

Get the next year of HEART ADVISOR for just $20. That's a savings of $19 off the regular rate.

With your paid subscription you will receive unlimited access to all of our online content. That is over a decade of previous issues from Cleveland Clinic, the hospital rated #1 in cardiac care by U.S. News & World Report - free of charge.

Subscriber Log In

Forgot your password? Click Here.

Already subscribe but haven't registered for all the benefits of the website? Click here.